
summari report sale result
acquisitions/divestitur top-lin result came
consensu estim
respect report adjust ep ahead
consensu estim print came ahead
expect driven q/q growth acceler nutrit
diagnost ex-alr epd establish pharmaceut divis
strong continu growth med devic organ worth
note abt robust top-lin growth led strength
ou busi organ call rais
organ sale growth guidanc adj
ep guidanc bracket
consensu repres growth
midpoint view guidanc rais reflect
underli strength abt broader businessespeci given
recent fx move regard guid organ sale growth
mid- high single-digit rang adj ep
chang estim lower sale estim
organ estim
wed note chang larg
reflect fx increas adj ep estim
rais estim
rais price target base
adj ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep includ stj amo alr
compani prioriti stock list
compani data secur llc estim reuter
sale ep top street expect report adjust ep beat
consensu estim guidanc ep upsid rel model reflect
higher revenu lower opex non-oper expens gross margin tax rate
line model total revenu organ ex-fx acquisit vs
estim beat consensu estim total us sale
organ fell shi forecast ou sale organ beat
estim nutrit sale ahead consensu estim
nutrit sale grew organ vs acceler larg driven faster
growth adult segment vs diagnost dx sale miss consensu
line forecast dx organ growth also acceler
ex-alr acquisit due faster growth lab molecular despit
declin sale poc point alr sale miss estim medic devic
sale beat consensu estim med devic growth
deceler vs level growth busi remain healthi organ epd sale
fell shi consensu forecast epd organ sale growth acceler
ex-fx
devic growth remain healthi post strong devic growth organ albeit
modestli level growth led diabet ex-fx electrophysiolog
ex-fx structur heart ex-fx pocket soft includ neuromodul
nm cardiac rhythm manag heart failur hf manag note nm growth
ex-fx primarili reflect disappoint spinal cord stimul growth
impact rep hire separ abt busi ex-fx partli impact
unfavor replac curv regard hf manag attribut weak lack
destin therapi dt indic heartmat guid med devic growth high-
singl digit addit manag rais full-year outlook devic high-single-digit growth
libr continu robust growth trajectori today call provid updat
launch libr continu progress ou manag said remain pleas earli
uptak libr ad patient total patient number
strong adopt translat sale ahead estim
given rapid uptak think libr sale full-year could well surpass
mark model ou libr adopt continu robust contribut
altogeth libr current user global expect finish year
patient
sequenti improv diagnost post dx growth ex-fx ex-alr
sequenti acceler vs growth ex-fx q/q acceler larg result faster
growth lab molecular dx contrast abt point poc busi declin
y/i due custom dynam integr rapid dx busi expect growth
mid high-singl digit rang ex-fx ex-alr full-year re-affirmed dx guidanc
mid- high-single-digit organ growth
epd bounc back face tough prior year comp epd sale growth improv
ex-fx line abt epd guidanc double-digit growth wed note epd
benefit rel easi prior year comp ex-fx relat destock ahead gst
good servic tax india epd driven double-digit growth china
india regard russia drag result manag note market begun
stabil expect return growth face challeng prior
year compar ex-fx relat inventori rebuild india follow implement
gst manag guid mid- high-singl growth y/i comp
also tough ex-fx sens remain confid full-year high-single-digit
outlook epd
nutrit show continu improv abt nutrit busi grew ex-fx
primarili driven faster growth adult segment vs
pediatr growth ex-fx led perform ou includ strong growth china latin
america adult nutrit also saw strength ou ex-fx driven ensur
glucerna brand full-year expect overal nutrit growth mid-single-
outlook rais despit fx chang today call increas top-
bottom-lin full-year guidanc compani expect organ sale growth ex-fx ex-
alr/amo past guidanc regard fx manag expect report sale
tailwind roughli wed note meaning lower previou fx guidanc due
strengthen dollar move full-year gross margin still expect
somewhat sg spend expect somewhat
sale respect despit unfavor fx move rais adj ep guidanc
repres growth midpoint separ alr
expect contribut littl report sale
guidanc introduc manag guid mid- high-single-digit organ sale growth
look abt guidanc busi epd expect grow mid high-singl digit nutrit
expect grow mid-singl digit dx expect mid high-singl digit med devic
expect grow high-singl digit manag expect fx advers impact
report sale regard alr expect alr contribut bottom-lin
guid adj ep bracket consensu
metricswfconsensusseg compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut medic technolog
price target
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid-singl digit underli
sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
 incom statement million except per share forma stj alr amo good sold fit fit includ includ med-tech fit fit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin fit fit compani report secur llc estim
